Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bendix Carstensen

Showing results (111-120 of 117) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 117 results.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
The Lancet. Diabetes & Endocrinology|November 9, 2025
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based studyJoanna Y Gong, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|March 12, 2026
Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based studyDianna J Magliano, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|January 13, 2022
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate dataDianna J Magliano, Lei Chen, Bendix Carstensen, et al.
The Lancet. Diabetes & Endocrinology|October 2, 2022
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|February 26, 2021
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settingsDianna J Magliano, Lei Chen, Rakibul M Islam, et al.
Pageof 12

Showing results (111-120 of 117) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 117 results.
Cardiovascular Diabetology|August 31, 2023
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and AsiaDorte Vistisen, Bendix Carstensen, Patorno Elisabetta, et al.
Diabetes & Metabolism|January 7, 2023
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) studyAvraham Karasik, Stefanie Lanzinger, Elise Chia-Hui Tan, et al.
The Lancet. Diabetes & Endocrinology|November 9, 2025
Time trends in mortality from heart failure and atherosclerotic cardiovascular disease in people with and without diabetes: a multi-national population-based studyJoanna Y Gong, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|March 12, 2026
Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based studyDianna J Magliano, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|January 13, 2022
Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate dataDianna J Magliano, Lei Chen, Bendix Carstensen, et al.
The Lancet. Diabetes & Endocrinology|October 2, 2022
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyDunya Tomic, Jedidiah I Morton, Lei Chen, et al.
The Lancet. Diabetes & Endocrinology|February 26, 2021
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settingsDianna J Magliano, Lei Chen, Rakibul M Islam, et al.
Pageof 12